News

Gene therapy helps counter hemophilia B

Enabling cells to make a clotting compound allows some patients to quit medication

By
1:38pm, December 13, 2011

A gene therapy based on a cargo-toting virus that gravitates to liver cells might provide hemophilia B patients with long-lasting protection against bleeding, an international team of scientists reports online December 10 in the New England Journal of Medicine.

Hemophilia B is the second-most common form of hemophilia, a hereditary disorder in which blood fails to clot properly. Patients must receive preventive injections of a clotting compound called factor IX to prevent bleeding from cuts, scratches or bruises. In the new study, four of six hemophilia B patients given the gene therapy no longer need the clotting compound.

This article is available only to subscribing members. Join SSP today or Log in.

More from this issue of Science News

[title_1]